Idorsia (IDIA.SW) Stock Price
Idorsia Price
Over the last 8 years Idorsia grew revenue by 4.3% annually, reaching 221.00 M CHF. For Idorsia, the net margin of -50.7% is up versus -1,795.2% a few years ago. The consensus 12-month price target for Idorsia is 4.59 CHF, about 2.7% above where the stock trades today. Of 10 analysts, 7 rate the stock a buy — an overall Buy consensus.
Idorsia stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Idorsia business model & stock analysis
Frequently asked questions about Idorsia
The business model of Idorsia Ltd revolves around the research, development, and commercialization of innovative pharmaceutical products. As a biopharmaceutical company, Idorsia focuses on discovering breakthrough therapies to address unmet medical needs. By leveraging its expertise in drug discovery and clinical development, Idorsia aims to bring novel treatments to patients worldwide. The company operates through collaborations with partners, strategic alliances, and the advancement of its own pipeline. With a commitment to scientific excellence and patient-centricity, Idorsia strives to improve the quality of life for individuals through the development of effective and safe medications.
Idorsia Ltd is primarily active in the pharmaceutical industry.
The main competitors of Idorsia Ltd in the market include big pharmaceutical companies such as Novartis, Roche, Pfizer, and GlaxoSmithKline. These companies also operate in the pharmaceutical industry and offer a range of products and services similar to Idorsia Ltd. Being a relatively new player in the market, Idorsia Ltd faces tough competition from these well-established competitors. However, Idorsia Ltd aims to differentiate itself through its innovative pharmaceutical pipeline and focus on developing novel treatments for various therapeutic areas.
Idorsia Ltd is a Swiss biopharmaceutical company specializing in the discovery, development, and commercialization of innovative therapeutic solutions. Founded in 2017 as a spin-off from Actelion Ltd, Idorsia boasts a rich history and strong foundation in the pharmaceutical industry. Building on the legacy of its predecessor, Idorsia has rapidly emerged as a key player in the development of novel treatments for various diseases and disorders. Led by an experienced management team, the company combines cutting-edge research with a focus on patient outcomes, striving to improve the lives of individuals worldwide. With its commitment to innovation and scientific excellence, Idorsia continues to make significant contributions to the field of biopharmaceuticals.
Idorsia Ltd has achieved several significant milestones in its history. The company, founded by renowned pharmaceutical entrepreneur Jean-Paul Clozel, made its debut on the SIX Swiss Exchange in June 2017. Since then, Idorsia has made remarkable progress in its drug development pipeline. One of the notable achievements of the company is the successful completion of Phase 3 clinical trials for their leading compound, daridorexant, a potential treatment for insomnia. Furthermore, Idorsia has also received regulatory approvals for the commercialization of several drugs, strengthening its presence in the pharmaceutical market. These achievements demonstrate Idorsia Ltd's commitment to innovation and its potential for future growth.
Idorsia Ltd is primarily present in Switzerland, where its headquarters are located. Aside from its domestic market, Idorsia has a global presence with operations and activities in various countries and regions. The company's focus on research and development of innovative therapies extends beyond Switzerland, reaching international markets. With a commitment to expanding its reach, Idorsia actively engages in collaborations, partnerships, and licensing agreements to further establish its presence worldwide. As a Swiss-based pharmaceutical company, Idorsia Ltd's prominence extends both locally and internationally as it strives to deliver groundbreaking medical solutions.
Idorsia Ltd represents a corporate philosophy focused on innovation, collaboration, and patient-centric healthcare. The company values excellence, integrity, and scientific rigor in all aspects of its operations. Idorsia is committed to developing breakthrough therapies and improving the lives of patients worldwide. With a strong emphasis on research and development, the company strives to deliver innovative solutions to unmet medical needs. By fostering a culture of continuous learning and teamwork, Idorsia aims to make a positive impact on the healthcare industry and contribute to the advancement of medicine.
Analysts currently set an average price target of 4.59 CHF for the Idorsia stock (median: 4.59 CHF), implying +2.7 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the Idorsia stock: 7 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Idorsia to generate revenue of 225.18 M CHF and earnings per share of -0.55 CHF.
Converted at the current exchange rate, the Idorsia share trades at 4.86 EUR (4.47 CHF).
The Idorsia share (IDIA.SW) is listed on 7 stock exchanges, including: London (0RQE.L), SIX (Zürich) (IDIA.SW), Frankfurt (19T.F), München (19T.MU), Düsseldorf (19T.DU), Hamburg (19T.HM).
Idorsia Ltd is a biopharmaceutical company based in Switzerland that focuses on the discovery, development, and commercialization of innovative therapies for mental and neurological disorders. The company consists of three main divisions: research and development, operations, and business development. The research and development division focuses on the discovery of new drugs and therapies for mental and neurological disorders, while operations is responsible for manufacturing and marketing the medications. Business development is involved in identifying potential business opportunities and developing partnerships and strategic alliances. Idorsia's core product is the insomnia medication Daridorexant. Daridorexant is a non-addictive medication that specifically targets the nerves in the brain to regulate the sleep-wake cycle. The medication has been proven to be safe and effective in clinical trials and is currently being submitted for approval by regulatory authorities. In addition to Daridorexant, Idorsia has a number of other medications in development that focus on various diseases and indications. The company is currently working on therapies for conditions such as schizophrenia, anxiety disorders, depression, and Alzheimer's disease. Idorsia is also working on a technology platform based on the identification of target molecules and the acceleration of drug development. This platform allows the company to develop new medications faster and more efficiently, ultimately leading to faster market release. To expand its product pipeline, Idorsia has also entered into several strategic alliances and partnerships with other biopharmaceutical companies. One such partnership is the collaboration with Japanese company Kyowa Kirin, where the two companies will focus on the development of therapies for severe sleep disorders. Idorsia utilizes an innovative business model designed to create value by reducing costs and risks in drug development. The company has a broad pipeline of drug candidates at various stages of development, from discovery to clinical development. This allows the company to achieve portfolio diversification and mitigate the risk of revenue loss. In summary, Idorsia is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for mental and neurological disorders. With an extensive portfolio of therapies and an innovative technology platform, the company is well-positioned to bring valuable medications to market that improve people's lives.
The expected revenue of Idorsia is 225.18 M CHF. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Idorsia is -136.84 M CHF. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Idorsia is currently -8.11. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Idorsia stock.
The price-to-sales ratio (P/S) of Idorsia is currently 4.93. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Idorsia stock.
The Eulerpool Quality Score for Idorsia is 3/10.
The ISIN of Idorsia is CH0363463438. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Idorsia is A2DTEB. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Idorsia is IDIA.SW. The ticker symbol is used to trade Idorsia shares on the stock exchange.
Idorsia stock
Idorsia Peer Group
Idorsia Ticker
Idorsia FIGI
All fundamentals and in-depth analysis of Idorsia
Our stock analysis for Idorsia stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Idorsia. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.